Liver fibrosis attributed to lipid lowering medications: two cases
Related Experiment Video
Updated: Oct 4, 2026

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease
Published on: July 19, 2024
Z Punthakee1, L J Scully, M M Guindi
1Department of Medicine, The Ottawa Hospital - Civic Campus, University of Ottawa, Ottawa, Ontario, Canada.
Abstract:
We identified two cases of chronic active hepatitis with liver fibrosis induced by lipid lowering drugs of the statin and fibrate classes despite regular monitoring of transaminases. There are few reports of clinically significant hepatitis induced by these drugs and even fewer cases of fibrosis. Given the growing use of these drugs, there are implications for monitoring patients on long-term therapy for liver damage.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Cirrhosis II: Pathophysiology
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Cirrhosis I: Introduction